These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30626714)

  • 1. Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion.
    Guo M; Wu F; Hu G; Chen L; Xu J; Xu P; Wang X; Li Y; Liu S; Zhang S; Huang Q; Fan J; Lv Z; Zhou M; Duan L; Liao T; Yang G; Tang K; Liu B; Liao X; Tao X; Jin Y
    Sci Transl Med; 2019 Jan; 11(474):. PubMed ID: 30626714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study.
    Dong X; Huang Y; Yi T; Hu C; Gao Q; Chen Y; Zhang J; Chen J; Liu L; Meng R; Zhang S; Dai X; Fei S; Jin Y; Yin P; Hu Y; Wu G
    Front Immunol; 2022; 13():1002938. PubMed ID: 36275698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion.
    Li X; Wu G; Chen C; Zhao Y; Zhu S; Song X; Yin J; Lv T; Song Y
    Front Immunol; 2021; 12():760683. PubMed ID: 34966384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion.
    Wang D; Yang L; Yue D; Cao L; Li L; Wang D; Ping Y; Shen Z; Zheng Y; Wang L; Zhang Y
    Cancer Lett; 2019 Jun; 452():244-253. PubMed ID: 30928379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer.
    Wu MF; Lin CA; Yuan TH; Yeh HY; Su SF; Guo CL; Chang GC; Li KC; Ho CC; Chen HW
    Cancer Immunol Immunother; 2021 May; 70(5):1435-1450. PubMed ID: 33175182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
    Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
    J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
    Psallidas I; Karabela SP; Moschos C; Sherrill TP; Kollintza A; Magkouta S; Theodoropoulou P; Roussos C; Blackwell TS; Kalomenidis I; Stathopoulos GT
    Mol Cancer; 2010 Mar; 9():56. PubMed ID: 20219102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.
    Psallidas I; Stathopoulos GT; Maniatis NA; Magkouta S; Moschos C; Karabela SP; Kollintza A; Simoes DC; Kardara M; Vassiliou S; Papiris SA; Roussos C; Kalomenidis I
    Oncogene; 2013 Jan; 32(4):528-35. PubMed ID: 22370646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapeutic Tumor Microparticles Elicit a Neutrophil Response Targeting Malignant Pleural Effusions.
    Xu P; Tang K; Ma J; Zhang H; Wang D; Zhu L; Chen J; Wei K; Liu J; Fang H; Tang L; Zhang Y; Xie J; Liu Y; Meng R; Liu L; Dong X; Yang K; Wu G; Ma F; Huang B
    Cancer Immunol Res; 2020 Sep; 8(9):1193-1205. PubMed ID: 32661094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of intrapleural hyperthermic perfusion on immunologic reaction state of cytokines TH1/TH2 of lung carcinoma patients with malignant pleural effusion].
    Kang MQ; Cao YP; Deng F
    Ai Zheng; 2008 Feb; 27(2):210-3. PubMed ID: 18279624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages.
    Li L; Yang L; Wang L; Wang F; Zhang Z; Li J; Yue D; Chen X; Ping Y; Huang L; Zhang B; Zhang Y
    Int J Cancer; 2016 Nov; 139(10):2261-9. PubMed ID: 27459735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
    Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
    J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.
    Zarogoulidis P; Chatzaki E; Hohenforst-Schmidt W; Goldberg EP; Galaktidou G; Kontakiotis T; Karamanos N; Zarogoulidis K
    Cancer Gene Ther; 2012 Sep; 19(9):593-600. PubMed ID: 22744209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-alpha promotes malignant pleural effusion.
    Stathopoulos GT; Kollintza A; Moschos C; Psallidas I; Sherrill TP; Pitsinos EN; Vassiliou S; Karatza M; Papiris SA; Graf D; Orphanidou D; Light RW; Roussos C; Blackwell TS; Kalomenidis I
    Cancer Res; 2007 Oct; 67(20):9825-34. PubMed ID: 17942913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.
    Yang L; Wang F; Wang L; Huang L; Wang J; Zhang B; Zhang Y
    Oncotarget; 2015 Apr; 6(12):10592-603. PubMed ID: 25871392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion.
    Liu Y; Wang L; Song Q; Ali M; Crowe WN; Kucera GL; Hawkins GA; Soker S; Thomas KW; Miller LD; Lu Y; Bellinger CR; Zhang W; Habib AA; Petty WJ; Zhao D
    Nat Nanotechnol; 2022 Feb; 17(2):206-216. PubMed ID: 34916656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.
    Stathopoulos GT; Sherrill TP; Karabela SP; Goleniewska K; Kalomenidis I; Roussos C; Fingleton B; Yull FE; Peebles RS; Blackwell TS
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1273-81. PubMed ID: 20595227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
    Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
    Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion.
    Ye ZJ; Zhou Q; Yin W; Yuan ML; Yang WB; Xiong XZ; Zhang JC; Shi HZ
    Am J Respir Crit Care Med; 2012 Dec; 186(11):1168-79. PubMed ID: 23065014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural effusion: tumor-host interactions unleashed.
    Stathopoulos GT; Kalomenidis I
    Am J Respir Crit Care Med; 2012 Sep; 186(6):487-92. PubMed ID: 22652027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.